Articles related to Pediatric Endocrinology

Past-year creatine use among U.S. adolescents roughly doubled between 2019 and 2024, even as anabolic steroid use continued a two-decade decline, according to a national survey of nearly 875,000 students.

A new Endocrine Society guideline favors watchful waiting over immediate evaluation for many girls with early breast development, narrows brain MRI and genetic testing to select cases, and sets age limits for stopping GnRH agonist therapy.

The FDA cleared the Dexcom Stelo Glucose Biosensor System for over-the-counter use in children ages 2 and older who do not use insulin, expanding a device previously limited to adults and supporting caregiver-supervised home glucose monitoring.

A JCEM clinical guidance article outlines a two-criterion diagnostic standard for adolescent PCOS, requiring both persistent hyperandrogenism and menstrual irregularity, and frames adolescence as the critical window for metabolic and psychosocial risk stratification.

The FDA approved inhaled insulin (Afrezza) for pediatric patients aged 6 and older with type 1 or type 2 diabetes, based on phase 3 trial data and long-term safety evidence from manufacturer-sponsored studies.

Pediatric patients who started automated insulin delivery within 6 months of type 1 diabetes diagnosis had a median HbA1c of 7.1% at 24 months versus 9.8% in non-users in a US multicenter retrospective cohort.